Accelerate Diagnostics Unveils Executive Incentive Plan Linked to FDA Goals
Company Announcements

Accelerate Diagnostics Unveils Executive Incentive Plan Linked to FDA Goals

An update from Accelerate Diagnostics (AXDX) is now available.

Accelerate Diagnostics, Inc. has rolled out an incentivizing plan for its top executives with a mix of long-term and performance-based rewards. Jack Phillips, David Patience, and Lawrence Mertz stand to gain from restricted stock units (RSUs) and performance stock units (PSUs), alongside hefty cash bonuses for the latter two, contingent on the company meeting specific FDA approval milestones for their Accelerate Wave system by the end of 2025. The RSUs are vested over three years, aiming to retain and motivate their executive team through direct equity ownership if the company’s strategic goals are met.

Learn more about AXDX stock on TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskAccelerate Diagnostics Reports Key Advances Amid Financial Challenges
Jason CarrAXDX Upcoming Earnings Report: What to Expect?
TheFlyAccelerate Diagnostics announces FDA clearance of Accelerate Arc system
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App